Vistagen Therapeutics Rallies: Is This The Beginning Of Full Recovery?

Vistagen Therapeutics, Inc. (VSTA) rose an incredible 10.89% yesterday, closing at a price of $1.12, which was also its intraday high. The stock had been on a declining streak since April and today’s rally could be another sign of volatility. Maybe, though, it’s a start for the company to climb back up.

On May 14th, Vistagen Therapeutics issued an update letter in a PR to its stockholders; a copy of the PR is attached on the current report of Form 8-K.

Vistagen Therapeutics is providing much flair in the field of drug rescue and cell therapy. The company also applies its expertise to therapeutic cell research.

Vistagen´s methods, along with its enviable experience in stem cell research, play an important part of any drug rescue. For the public use, the company scrutinizes all of its drugs very proficiently before sending them in to the market. Several drugs were abandoned after indications that they could cause adverse effects to the human heart, which has been corroborated by the National Institute of Health, drug development companies, and academic research laboratories.

Vistagen also secures vital US patents for stem cell investigation. Recently, Vistagen has been awarded patent 11/445,733. This patent incorporates the methods and forms of measuring poisonous outcomes potentially reduced by trial drugs in the stems of liver cells.

Also included in patent 11/445,733 is the authority to utilize all cells derived from small rodent liver cells, including rats and mice.

Next line permission has also been granted for testing cells in ´vivo´ organisms or cells from pluripotent-provoked sources. The company can also monitor toxic changes in genes. This patent permits the company to monitor changes in the genes as a way of predicting drug toxins.

For consideration of being featured on WallstreetPR, contact:

Please make sure to read and completely understand our disclaimer at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at

Published by Donna Fago

I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at recently due to my passion for the markets.